8.61
0.04 (0.47%)
| Penutupan Terdahulu | 8.57 |
| Buka | 8.57 |
| Jumlah Dagangan | 549,838 |
| Purata Dagangan (3B) | 1,062,124 |
| Modal Pasaran | 484,721,760 |
| Harga / Pendapatan (P/E TTM) | 18.32 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.90 |
| Harga / Jualan (P/S) | 5.83 |
| Harga / Buku (P/B) | 3.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -226.64% |
| Margin Operasi (TTM) | -26.28% |
| EPS Cair (TTM) | -1.94 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 495.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 150.74% |
| Nisbah Semasa (MRQ) | 3.02 |
| Aliran Tunai Operasi (OCF TTM) | -61.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.23 M |
| Pulangan Atas Aset (ROA TTM) | -27.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -204.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Zevra Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.25 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.69% |
| % Dimiliki oleh Institusi | 65.42% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ |
| 02 Feb 2026 | Pengumuman | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 |
| 26 Jan 2026 | Pengumuman | Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ |
| 08 Jan 2026 | Pengumuman | Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference |
| 29 Dec 2025 | Pengumuman | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) |
| 12 Dec 2025 | Pengumuman | Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |